Exacerbations · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics probably leads to lower number of people with one or more exacerbations WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Annual Exacerbation Rates · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics probably leads to lower rate of exacerbation per patient/year WMD of compared with placebo (moderate certainty).
1 finding from 1 review
HRQoL: total score · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
1 finding from 1 review
All‐cause mortality WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in all‐cause mortality WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in serious adverse events WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Any adverse event WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in any adverse event WMD of compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
1 finding from 1 review
Annual Exacerbation Rates · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Change in quality of life: SGRQ Scale: 0 to 100 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Pneumonia · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS may leads to higher pneumonia compared with placebo (low certainty).
1 finding from 1 review
Oropharyngeal candidiasis · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS probably leads to higher oropharyngeal candidiasis compared with placebo (moderate certainty).
1 finding from 1 review
Outcomes (weighted · stable COPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate‐to‐severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower moderate‐to‐severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline (lower scores indicate better HRQoL) · stable COPD
Triple therapy leads to higher respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline… compared with LABA/LAMA combination (high certainty).
1 finding from 1 review
Pneumonia (labelled as an SAE) · stable COPD
Triple therapy probably leads to higher pneumonia (labelled as an SAE) compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review
SAEs · stable COPD
Triple therapy showed no clear difference in all‐cause SAEs compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Symptoms of dyspnoea · stable COPD
Triple therapy probably leads to higher symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse… compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review